SAN DIEGO, Calif.--A study undertaken by Nanogen and the Pediatric Oncology Branch of the US National Cancer Institute describing advances in Nanogen's single-nucleotide polymorphism discrimination technology was published in Nature Biotechnology this month.
The article, "Single nucleotide polymorphic discrimination by an electronic dot blot assay on semiconductor microchips," reports on the use of microchips to identify variants of the mannose binding protein gene that differ from one another by only a single DNA base. Researchers used Nanogen's proprietary semiconductor microchips to identify polymorphisms in the gene that codes for mannose binding protein. The protein is a key component of the innate immune system in children who have not yet developed an immunity to a variety of pathogens. The study tested the ability of the Nanogen platform to perform accurate multiplexed assays.
Howard Birndorf, Nanogen's chairman and CEO, said the data indicated that Nanogen's semiconductor microchip array technology is "well suited to perform these analyses quickly." Birndorf added, "As SNPs become associated with a growing number of diseases, it is becoming increasingly clear that rapid, accurate identification of an individual's genetic profile will enhance a physician's ability to prescribe optimal treatment for his or her patient."